Прогностическое значение мозгового натрийуретического пептида для оценки риска сердечно-сосудистых осложнений при внесердечных хирургических вмешательствах

Частота осложнений, связанных с оперативным вмешательством, за последние 30 лет существенно снизилась, однако последствия после хирургических манипуляций все еще являются серьезной клинической проблемой. Выявление интра- и послеоперационного повреждения миокарда является сложной задачей, поскольку почти половина всех осложнений отмечается у пациентов, исходно не входящих в группу высокого риска без заболеваний сердца в анамнезе. В настоящее время несколько крупных исследований и метаанализов, результаты которых были опубликованы за последние 5 лет, рекомендуют использование определения мозговых натрийуретических пептидов для стратификации риска у всех пациентов, готовящихся к плановой внесердечной хирургической операции, с целью улучшения послеоперационного исхода. Мониторинг уровня натрийуретических пептидов у пациентов в течение всего пери-операционного периода может способствовать лучшему пониманию патофизиологии развития кардиальных осложнений при внесердечных хирургических вмешательствах. Внедрение новых критериев позволит качественно улучшить оказание помощи коморбидным пациентам, снизить количество послеоперационных осложнений и улучшить междисциплинарные взаимодействия специалистов в рамках командной работы.

1. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e77-137. doi:10.1016/j.jacc.2014.07.944.

2. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383-431. doi:10.1097/EJA.0000000000000150.

3. Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol. 2017;33(1 ):17-32. doi:10.1016/j.cjca.2016.09.008.

4. De Hert S, Staender S, Fritsch G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2018;35:407-65. doi:10.1097/EJA.0000000000000817.

5. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: A metaanalysis. Arch Intern Med. 2010;170(6):507-14. doi:10.1001/archinternmed.2010.35.

6. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010;121:2388-97 doi:10.1161/CIRCULATIONAHA.109.901413.

7. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9. doi:10.1007/s12170-009-0021-z.

8. Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol. 2009;54:1599-606. doi: 10.1016/j.jacc.2013.08.1630.

9. Ryding AD, Kumar S, Worthington AM, et al. Prognostic value of brain natriuretic peptide in noncardiac surgery: a meta-analysis. Anesthesiol. 2009;111:311-19. doi: 10.1097/ALN.0b013e3181aaeb11.

10. Rodseth RN, Padayachee L, Biccard BM. A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia. 2008;63:1226-33. doi:10.1111/j.1365-2044.2008.05574.x.

11. Rodseth RN, Lurati Buse GA, Bolliger D, et al. The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. J Am Coll Cardiol. 2011;58:522-9. doi: 10.1016/j.jacc.2011.04.018.

12. PeriOperative ISchemic Evaluation-3 Trial. https://clinicaltrials.gov/ct2/show/NCT03505723.

13. Filipovic M, Kindler CH, Walder B. Anasthesiologie und Reanimation: Perioperative kardiale Abklarung und Therapie im Vorfeld nicht-herzchirurgischer Eingriffe. Swiss Med. Forum Schweiz. Med. 2018;18:1078-80. doi:10.4414/smf.2018.03440.

14. Biccard BM, Naidoo P, De Vasconcellos K. What is the best pre-operative risk stratification tool for major adverse cardiac events following elective vascular surgery? A prospective observational cohort study evaluating pre-operative myocardial ischaemia monitoring and biomarker analysis. Anaesthesia. 2012;67:389-95. doi:10.1111/j.1365-2044.2011.07020.x.

15. Shimizu Y, Nishinaga M, Takata J, et al. B-type natriuretic peptide is predictive of hospitalization in community-dwelling elderly without heart diseases. Geriatr Gerontol Int. 2009;9:148-54. doi:10.1186/2049-6958-9-59.

16. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-63. doi:10.1056/NEJMoa031994.

17. Witham MD, Gillespie ND, Hutcheon SD, et al. B-type natriuretic peptide is associated with mortality in older functionally impaired patients. J Am Geriatr Soc. 2005;53:1991-5. doi: 10.1016/j.jacc.2018.02.071.

18. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50:205-14. doi:10.1016/j.jacc.200703.038.

19. Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625. doi:10.1136/bmj.330.7492.625.

20. Shang C. B-type natriuretic peptide-guided therapy for perioperative medicine? Open Heart 2014;1:e000105. doi:10.1136/openhrt-2014-000105.

21. Gibson SC, Payne CJ, Byrne DS, et al. B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery. Br J Surg. 2007;94. doi:903-910.1002/bjs.5690.

22. Ford MK, Beattie WS, Wijeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010;152:26-35. doi:10.7326/0003-4819-152-1-201001050-00007

23. Yun KH, Jeong MH, Oh SK, et al. Preoperative plasma N-terminal pro-brain natriuretic peptide concentration and perioperative cardiovascular risk in elderly patients. Circ J. 2008;72:195-9. doi:10.1253/circj.72.195.

24. Choi JH, Cho DK, Song YB, et al. Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. Heart. 2010;96:56-62. doi: 10.1136/hrt.2009.181388.

25. Toscano FV, Apinis A, Leff JD. Pre-operative Risk Stratification Update for Cardiac and Major Vascular Surgery. Curr Anesthesiol Rep. 2015;5:445-51. doi:10.1007/s40140-015-0136-3.

26. Cuthbertson BH, Amiri AR, Croal BL, et al. Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. Br J Anaesth. 2007;99:170-6. doi:10.1093/bja/aem158.

27. Kistorp C, Raymond I, Pedersen F, et al. N-terminal probrain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609-16. doi:10.1001/jama.293.13.1609.

28. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55:2140-7 doi:10.1016/j.jacc.2010.01.031.

29. Daniels LB. Natriuretic peptides and assessment of cardiovascular disease risk in asymptomatic persons. Curr Cardiovasc Risk Rep. 2010;4:120-7 doi:10.1007/s12170-010-0078-8.

30. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54:e13-8. doi:10.1016/j.jacc.2009.07.010.

31. Wolf PA, Abott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med. 1987;147:1561-4.

32. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378:2191-201. doi:10.1056/NEJMc1809065.

33. McIntyre WF, Connolly SJ, Healey JS. Atrial fibrillation occurring transiently with stress. Curr Opin Cardiol. 2018;33(1):58-65. doi:10.1097/HCO.0000000000000475.

34. McIntyre WF, Healey JS. Stroke prevention for patients with atrial fibrillation: beyond the guidelines. J Atr Fibrillation. 2017;91(6):1-7 doi:10.4022/jafib.1475.

35. Gialdini G, Nearing K, Bhave PD, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA. 2014;312(6):616-22. doi:10.1001/jama.2014.9143.

36. Simmers D, Potgieter D, Ryan L, et al. The use of preoperative B-type natriuretic peptide as a predictor of atrial fibrillation after thoracic surgery: systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29:389-95. doi: 10.1053/j.jvca.2014.05.015.

37. Rodseth RN, Biccard BM, Chu R, et al. Postoperative B-type natriuretic peptide for prediction of major cardiac events in patients undergoing noncardiac surgery: Systematic review and individual patient meta-analysis. Anesthesiology. 2013; 119:27083. doi:10.1097/ALN.0b013e31829083f1.

38. Cardinale D, Colombo A, Sandri MT, et al. Increased perioperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer. Circulation. 2007;115:1339-44. doi: 10.1161/CIRCULATIONAHA.106.647008.

39. Cardinale D, Sandri MT, Colombo A, et al. Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. Ann Surg. 2016;264:244-51. doi: 10.1097/SLA.0000000000001626.

40. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation. 2004;110:124-7 doi:10.1161/01.CIR.0000134481.24511.BC.

41. Nojiri T, Maeda H, Takeuchi Y, et al. Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer. Eur J Cardiothorac Surg. 2010;37:787-91. doi:10.1016/j.ejcts.2009.09.043.

42. Yoshimura M, Mizuno Y, Nakayama M, et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med. 2002;112:716-20. doi:10.1016/S0002-9343(02)01121-X.

43. Cai GL, Chen J, Hu CB, et al. Value of plasma brain natriuretic peptide levels for predicting postoperative atrial fibrillation: A systemic review and meta-analysis. World J Surg. 2014;38:51-9. doi:10.1007/s00268-013-2284-2.

44. Fabiani I, Colombo A, Bacchiani G, et al. Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology. J Clin Med. 2019;9(1):37 doi:10.3390/jcm9010037.